75.61 
0.64(0.85%) 11:39AM EDT
| Prev Close: | 75.61 |
|---|
| Open: | 75.24 |
|---|
| Bid: | 75.61 |
|---|
| Ask: | 75.63 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 75.01 - 75.61 |
|---|
| 52wk Range: | 23.74 - 75.61 |
|---|
| Volume: | 2,046,460 |
|---|
| Avg Vol (3m): | 8,517 |
|---|
| Market Cap: | 100.25B |
|---|
| P/E (ttm): | 29.20 |
|---|
| EPS (ttm): | 2.59 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in EUR.
Headlines
- Merck to slash annual costs by $2.5 billion, cut 8,500 jobsReuters(Tue 2:08PM EDT)
- Merck to slash annual costs by $2.5 bln, cut 8,500 jobsReuters(Tue 2:06PM EDT)
- Genzyme Announces Winners of Patient Advocacy Leadership (PAL) AwardsBusiness Wire(Mon, Sep 30)
- Pharma industry should support China curbs on corruption: Sanofi CEOReuters(Mon, Sep 30)
- Nestlé scrutinises its L'Oréal stakeat Financial Times(Sun, Sep 29)
- Genzyme’s Multiple Sclerosis Franchise Featured at ECTRIMSBusiness Wire(Thu, Sep 26)
- Sanofi Seeks Regional Alliances to Bulk Up Diabetes Offeringat Bloomberg(Wed, Sep 25)
- Lilly Bets Quality Will Pay Off in U.S. Diabetes Battleat Bloomberg(Tue, Sep 24)
- Bribery allegations infect drug companies' deals in Chinaat Financial Times(Mon, Sep 23)
- Sanofi Settles Lawsuit Over Obesity Drug for $40 Millionat Bloomberg(Thu, Sep 19)
- ViroPharma Drug Appeal Seen Driving 50% Return: Real M&Aat Bloomberg(Thu, Sep 19)
- Sanofi Forms Partnership with UMass Boston with $1 Million Support of Student Success Program for STEM EducationBusiness Wire(Thu, Sep 19)
- Analysis: Bribery scandal dents Big Pharma sales in China, GSK hardest hitReuters(Wed, Sep 18)
- [$$] Sanofi's MS Drug Lemtrada Receives Approval in Europeat The Wall Street Journal(Tue, Sep 17)
- European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada™ (alemtuzumab)Business Wire(Tue, Sep 17)
Reports
- No Reports available for SAN.PA at this time.
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 2.94 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments.
View More